Mr. Francesco Rinaldi studied Pharmacy at Alma Mater Studiorum - University of Bologna. From September 2016 to March 2017 he performed the Pharmacy Internship at the Maggiore Hospital in Bologna (AUSL Bologna). In 2017 Mr. Rinaldi moved to the Italian Institute of Technology in Genoa for a 3 months inthernship period working on the expression and the purification of proteins of pharmaceutical interest. Then, he spent 6 months, at ETH Zurich in Prof. Dario Neri Biomacromolecules group, to perform his Master Thesis, focused on the development of new monoclonal antibodies. His master thesis contributed to a paper, published on Leukemia Research in June 2019, entitled "Development of a new monoclonal antibody against CD123 for the treatment of Acute Myeloid Lekaemia".
In March 2018 he graduated in Pharmacy with a final mark of 110/110 cum laude. Later in June he passed the State Examination for Pharmacists with the overall mark of 292/350. He is enrolled as a member of the Bologna Pharmacist order.
During 2018 he followed the Summer School in Metodology of Clinical Research and the training course "Education of the Community Pharmacist" organized by Prof. Maurizio Cini, at University of Bologna.
Mr. Rinaldi has been External Collaborator in Prof. Andrea Cavalli Computational and Chemical Biology group from January 2019 to October 2019, working on the expression and purification of a monomeric form of RAD51,for the validation of new chemical compounds and peptides as protein inhibitors.
Since November 2019 is a PhD Fellow in Prof. Andrea Cavalli group grading first after the selection process at the Alma Mater Studiorum - University of Bologna and working on a project entitled "Innovative approaches to overcome drug-resistance in cancer".
In November 2020 Mr. Francesco Rinaldi has been awarded of a triennal FIRC-AIRC fellowship for a project entitled "Unveiling the molecular mechanism of BRCA2-RAD51 interaction to tackle cancer onset"